BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Mersana scores $100M up front for preclinical STING ADC in potential $1.5B GSK deal
Mersana Therapeutics Inc. is getting $100 million up front in an option deal with GSK plc for preclinical-stage antibody-drug conjugate (ADC) XMT-2056, which could bring up...

More in BioWorld

BioWorld MedTech

FDA advances AI-enhanced tech for prostate diagnosis and treatment
Recent U.S. FDA actions could transform decades of prostate cancer care. Two companies focused on prostate cancer received good news from the FDA for their artificial...

More in BioWorld MedTech

BioWorld Science

AIDS 2022: Scientists report progress in understanding how to eliminate latent HIV reservoirs
Researchers around the world are making advances in understanding how HIV becomes latent and seeking out vulnerabilities that could provide routes to targeting reservoirs and eliminating them.

More in BioWorld Science

BioWorld Asia

Shionogi, Grünenthal ink licensing deal worth $525M for injectable osteoarthritis pain drug
Shionogi & Co. Ltd. has in-licensed Japan rights to Grunenthal GmbH’s intra-articular injectable, resiniferatoxin, for the treatment of pain associated with osteoarthritis...

More in BioWorld Asia

BioWorld Insider Podcast

In Extending the human lifespan, a BioWorld special report, the team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing potential “Fountain of Youth” candidate drugs. In this episode of the BioWorld Insider Podcast, the team discussed the report’s highlights and key takeaways.